Variation in intravenous iron use internationally and over time: The Dialysis Outcomes and Practice Patterns Study (DOPPS)

Nephrology Dialysis Transplantation

Volumn 28, Issue 10, 2013, Pages 2570-2579

  Bailie, George R ^a   Larkina, Maria ^b   Goodkin, David A ^b   Li, Yun ^b,c   Pisoni, Ronald L ^b   Bieber, Brian ^b   Mason, Nancy ^c   Tong, Lin ^b   Locatelli, Francesco ^d   Marshall, Mark R ^e   Inaba, Masaki ^f   Robinson, Bruce M ^b,c  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d A MANZONI HOSPITAL   (Italy)

^e MIDDLEMORE HOSPITAL   (New Zealand)

^f OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

hemodialysis; international trends; intravenous iron; iron stores; prescription patterns

Indexed keywords

CHONDROITIN SULFATE IRON; FERRIC GLUCONATE; FERRIC HYDROXIDE; FERRITIN; IRON; IRON DEXTRAN; IRON POLYMALTOSE; IRON SACCHARATE; TRANSFERRIN;

ANEMIA; ARTICLE; AUSTRALIA; CANADA; CLINICAL PRACTICE; DRUG USE; EUROPE; FERRITIN BLOOD LEVEL; FRANCE; GERMANY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; ITALY; JAPAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; NEW ZEALAND; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES;

HEMODIALYSIS; INTERNATIONAL TRENDS; INTRAVENOUS IRON; IRON STORES; PRESCRIPTION PATTERNS;

ANEMIA; FOLLOW-UP STUDIES; HUMANS; IRON; KIDNEY DISEASES; PHYSICIAN'S PRACTICE PATTERNS; PROGNOSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 84884917017     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft062     Document Type: Article

References (59)

1. Pisoni RL, Bragg-Gresham J, Young EWet al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study. Am J Kidney Dis 2004; 44: 94-111 (Pubitemid 38880932)
2. US Renal Data System. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD, 2010 http://www.usrds.org/2009/pdf/V2-00A-PRECIS-09.PDF. Accessed 15 September 2010
3. McFarlane PA, Pisoni RL, Eichleay MA et al. International trends in erythropoietin use and hemoglobin levels in hemodialysis patients. Kidney Int 2010; 78: 215-223
4. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590 (Pubitemid 28385655)
5. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084 (Pubitemid 44749316)
6. Singh AK, Szczeck L, Tang KL et al. Correction of anemia with epoetin alpha in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098 (Pubitemid 44749317)
7. Pfeffer MA, Burdmann EA, Chen C-Y et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
8. FDA Drug Safety Communication: modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease. US Food and Drug Administration, Bethesda, MD. (24 June 2011, date last accessed)
9. Hasegawa T, Bragg-Gresham JL, Pisoni RL et al. Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin. Kidney Int 2011; 79: 340-346
10. DOPPS Practice Monitor: Emerging Trends. 2012. http://www. dopps.org/DPM/(26 June 2012, date last accessed)
11. Szuchs TD, Blank PR, Schwenkglenks M et al. Potential health economic impact of intravenous iron supplementation to erythropoiesis- stimulating agent treatment in patients with canceror chemotherapy-induced anemia. Oncology 2011; 81: 45-49
12. Shaheen FAM, Souqiyyeh MZ, Akeel N. Effect of intravenous iron saccharate on the requirements of erythropoietin in hemodialysis patients. Saudi J Kidney Dis Transplant 2002; 13: 131-140
13. Singh H, Reed J, Noble S et al. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial. Clin J Am Soc Nephrol 2006; 1: 475-482
14. Scheisser D, Binet I, Tsinalis D et al. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. Nephrol Dial Transplant 2006; 21: 2841-2845 (Pubitemid 44542240)
15. Evstatiev R, Marteau P, Igbal T et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011; 141: 846-853
16. Krafft A, Breymann C. Iron sucrose with and without recombinant erythropoietin for the treatment of severe postpartum anemia: a prospective, randomized, open-label study. J Obstet Gynaecol Res 2011; 37: 119-124
17. Khalafallah A, Dennis A, Bates J et al. A prospective, randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency of pregnancy. J InternMed 2010; 268: 286-295
18. Van Wyck DB, Mangione A, Morrison J et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009; 49: 2719-2728
19. Anker SD, Comin Colet J, Filippatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-2448
20. Bastit A, Vandebroek A, Altintas S et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008; 26: 1611-1618
21. Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 2010; 116: 522-525
22. Breymann C, Gliga F, Bejenariu C et al. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency. Int J Gynecol Obstet 2008 doi:101016/j.ijgo.2007.10.009
23. Bayoumeu F, Subiran-Buisset C, Baka N-E et al. Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route. Am J Obstet Gynecol 2002; 186: 518-522
24. Love AL, Billett HH. Obesity, bariatric surgery, and iron deficiency: true, true, and related. Am J Hematol 2007; 83: 403-409
25. Bolger AP, Bartlett FR, Penston HS et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006; 48: 1225-1227 (Pubitemid 44345150)
26. Gasche C, Berstad A, Befrits R et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007; 13: 1545-1553
27. Rodgers GM, Becker PS, Bennett CL et al. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: cancer- and chemotherapy-induced anemia. V1. 2013. http://www.nccn.org/professionals/ physician-gls/pdf/anemia.pdf (17 March 2013, date last accessed)
28. Anaemia management in chronic kidney disease. Rapid Update 2011/National Clinical Guideline Centre. London: National Institute of Health and Clinical Excellence. Royal College of Physicians. February 2011
29. KDIGO Clinical practice guidelines for anaemia in CKD. Draft September 2011 Kidney Int Suppl 2012; 2: 279-335
30. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target. http://www.kidney.org/professionals/KDOQI/guidelines-anemiaUP/index.htm (17 March 2013, date last accessed)
31. Caring for Australasians with Renal Impairment Clinical Practice Guidelines for Dialysis: Biochemical and Haematological Tests (Haemoglobin, 2011 and Iron, 2006). http://www.cari.org.au/dialysis-bht-published.php (17 March 2013, date last accessed)
32. Locatelli F, Covic A, Eckhardt K-U et al. ERA-EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: position statement by the Anaemia Working Group of European Renal Best Practice (ERBP), 2008. Nephrol Dial Transplant 2009; 24: 348-354
33. Canadian Society of Nephrology Clinical Practice Guidelines for the management of anemia associated with chronic kidney disease, 2008. Kidney Int 2008; 74: S1-24
34. Tsubakihara Y, Nishi S, Akiba T et al. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial 2010; 14: 240-275
35. Bailie GR, Clark JA, Lane CE et al. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 2005; 20: 1443-1449 (Pubitemid 41430619)
36. Wysowski DK, Swartz L, Borders-Hemphill BV et al. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol 2010; 85: 650-654
37. Bailie GR, Hoerl WH, Verhoef JJ. Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America. Arzneimittelforschung 2011; 61: 267-275
38. Feldman HI, Joffe M, Robinson B et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004; 15: 1623-1632 (Pubitemid 38679688)
39. Kalantar-Zadeh K, Regidor DL, McAllister CJ et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3070-3080 (Pubitemid 44743505)
40. Heinze G, Kainz A, Horl WH et al. Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study. BMJ 2009; 339: b4018
41. Brookhart MA, Schneeweiss S, Avorn J et al. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA 2010; 303: 857-864
42. Brewster UC. Intravenous iron therapy in end-stage renal disease. Semin Dial 2006; 19: 285-290 (Pubitemid 44091702)
43. Kuo K-L, Hung S-C, Sei Y-H et al. Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. J Am Soc Nephrol 2008; 19: 1817-1826
44. Bailie GR. Comparison of rates of reported adverse events associated with i.v. iron products in the United States. Am J Health Sys Pharm 2012; 69: 310-320
45. MacDougall IC, McGlaughlin J, Fortin GS et al. FIRST: head-tohead comparison study (ferumoxytol compared to iron sucrose trial) of the safety and efficacy of ferumoxytol with iron sucrose for the treatment of iron deficiency anemia in patients with chronic kidney disease. J Am Soc Nephrol 2011; 22: 6B (abstract)
46. Young EW, Goodkin DA, Mapes DL et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS): an international hemodialysis study. Kidney Int Suppl 2000; 74: S74-S81
47. Goodkin DA, Mapes DL, Held PJ. The Dialysis Outcomes and Practice Patterns Study (DOPPS): how can we improve the care of hemodialysis patients? Semin Dial 2001; 14: 157-159. (Pubitemid 33720848)
48. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13-22
49. Akizawa T, Pisoni RL, Akiba T et al. Japanese haemodialysis anaemia management practices and outcomes (1999-2006): results from the DOPPS. Nephrol Dial Transplant 2008; 23: 3643-3653
50. Chertow GM, Mason PD, Vaage-Nilsen O et al. Update on adverse events associated with parenteral iron. Nephrol Dial Transplant 2006; 21: 378-382 (Pubitemid 43159991)
51. Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy and safety. Hematology 2010 doi:10.1182/asheducation- 2010.1.338
52. Shimamatsu K. Experience with IV iron chondroitin sulfate colloid in Japanese haemodialysis patients. Nephrol Dial Transplant 1998; 13: 1053 (Pubitemid 28161804)
53. Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung 1992; 42: 1439-1452 (Pubitemid 23007362)
54. Espósito BP, Breuer W, Slotki I et al. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin- bound iron in dialysis patients. Eur J Clin Invest 2002; 32: 42-49 (Pubitemid 41704987)
55. Rostoker G, Griuncelli M, Loridon C et al. Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med 2012; 125: 991-999
56. Low CL, Bailie GR, Eisele G. Sensitivity and specificity of transferrin saturation and serum ferritin as markers of iron status after intravenous iron dextran in hemodialysis patients. Ren Fail 1997; 19: 781-786
57. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006; 1: S4-S8
58. United States Food and Drug Administration. US Department of Health and Human Services. FDA Drug Safety Communication. Modified dosing recommendations to improve the safe use of erythropoiesis- stimulating agents (ESAs) in chronic kidney disease. 24 June 2011. http://www.fda.gov/Drugs/DrugSafety/ucm259639. htm. (2 January 2013, date last accessed)
59. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Inter Suppl. 2012; 2: 279-335. http://www.kdigo.org/clinical-practice- guidelines/Anemia.php. (26 June 2012 date last accessed)